Karyopharm TherapeuticsKPTI
KPTI
About: Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.
Employees: 279
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
512% more call options, than puts
Call options by funds: $581K | Put options by funds: $95K
5.35% less ownership
Funds ownership: 48.27% [Q4 2024] → 42.92% (-5.35%) [Q1 2025]
46% less funds holding
Funds holding: 87 [Q4 2024] → 47 (-40) [Q1 2025]
67% less capital invested
Capital invested by funds: $41.2M [Q4 2024] → $13.7M (-$27.5M) [Q1 2025]
95% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 42
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 45
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$10
128%
upside
Avg. target
$28
545%
upside
High target
$42
857%
upside
3 analyst ratings
3 positive
100%
0 neutral
0%
0 negative
0%
RBC Capital Brian Abrahams | 652%upside $33 | Outperform Maintained | 13 May 2025 |
Barclays Peter Lawson | 128%upside $10 | Overweight Maintained | 13 May 2025 |
Baird Michael Ulz | 857%upside $42 | Outperform Maintained | 13 May 2025 |
Financial journalist opinion
Based on 5 articles about KPTI published over the past 30 days
Neutral
PRNewsWire
1 week ago
Karyopharm to Present at the Jefferies Global Healthcare Conference
NEWTON, Mass. , June 3, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team is scheduled to present at the Jefferies Global Healthcare Conference on Thursday, June 5, 2025 at 3:10 p.m.
Neutral
PRNewsWire
1 week ago
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEWTON, Mass. , June 2, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate of 566 restricted stock units (RSUs) to two newly-hired employees.
Positive
Zacks Investment Research
2 weeks ago
Here's Why Karyopharm Therapeutics (KPTI) Is a Great 'Buy the Bottom' Stock Now
Karyopharm Therapeutics (KPTI) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Positive
Zacks Investment Research
3 weeks ago
Does Karyopharm Therapeutics (KPTI) Have the Potential to Rally 521.62% as Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 521.6% in Karyopharm Therapeutics (KPTI). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Neutral
PRNewsWire
3 weeks ago
Karyopharm to Participate at the 2025 RBC Capital Markets Global Healthcare Conference
NEWTON, Mass. , May 19, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team will participate at the 2025 RBC Capital Markets Global Healthcare Conference in a fireside chat on Wednesday, May 21 at 10:00 a.m.
Neutral
PRNewsWire
1 month ago
Karyopharm Announces Poster Presentation on Selinexor in Myelofibrosis at the 2025 European Hematology Association Annual Meeting
NEWTON, Mass. , May 14, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced its abstract has been selected for a poster presentation at the 2025 European Hematology Association Annual Meeting (EHA) being held June 12-15 in Milan, Italy.
Neutral
Benzinga
1 month ago
These Analysts Revise Their Forecasts On Karyopharm Therapeutics After Q1 Results
Karyopharm Therapeutics Inc. KPTI reported mixed financial results for the first quarter on Monday.
Neutral
Seeking Alpha
1 month ago
Karyopharm Therapeutics Inc. (KPTI) Q1 2025 Earnings Call Transcript
Karyopharm Therapeutics Inc. (NASDAQ:KPTI ) Q1 2025 Earnings Conference Call May 12, 2025 4:30 PM ET Company Participants Brendan Strong - Senior Vice President, Investor Relations & Corporate Communications Richard Paulson - President & Chief Executive Officer Reshma Rangwala - Chief Medical Officer & Head, Research Sohanya Cheng - Chief Commercial Officer & Head, Business Development Lori Macomber - Chief Financial Officer & Treasurer Conference Call Participants Colleen Kusy - Baird Ted Tenthoff - Piper Sandler Peter Lawson - Barclays Albert Agustinus - Leerink Partners Operator Good afternoon. My name is Chloe, and I will be your conference operator today.
Negative
Zacks Investment Research
1 month ago
Karyopharm Therapeutics (KPTI) Reports Q1 Loss, Lags Revenue Estimates
Karyopharm Therapeutics (KPTI) came out with a quarterly loss of $2.77 per share versus the Zacks Consensus Estimate of a loss of $4.21. This compares to loss of $4.80 per share a year ago.
Neutral
PRNewsWire
1 month ago
Karyopharm Reports First Quarter 2025 Financial Results and Announces New Data in Myelofibrosis that Further Suggests Selinexor May Lead to Meaningful Spleen Volume Reduction, Symptom Improvement, Hemoglobin Stabilization and Disease Modification
– New Randomized Phase 2 Monotherapy Data from XPORT-MF-035 Trial in a Hard-to-Treat Patient Population Further Strengthens Conviction in Selinexor's Potential in Combination with Ruxolitinib in JAKi-Naïve Myelofibrosis in Ongoing Phase 3 SENTRY Trial – – Phase 3 SENTRY Trial Passed Planned Futility Analysis; Trial is Approximately 80% Enrolled with Target Enrollment Expected in June/July 2025 – – Demand for XPOVIO® (selinexor) Increased 5% in the First Quarter of 2025 Compared to the First Quarter of 2024; Total Revenue was $30.0 Million; U.S. XPOVIO® Net Product Revenue of $21.1 Million was Adversely Impacted by a $5.0 Million Increase in the Product Return Reserve due to Atypical Returns of Expired 80 mg and 100 mg Units – – Reaffirms Full-Year 2025 Total Revenue Guidance of $140 Million to $155 Million, Including U.S. XPOVIO Net Product Revenue Guidance of $115 Million to $130 Million – – Company is Exploring Various Alternatives to Extend Cash Runway – – Conference Call Scheduled for Today at 4:30 p.m. ET – NEWTON, Mass.
Charts implemented using Lightweight Charts™